molibresib (GSK525762) / GSK - LARVOL DELTA

Small Molecule Cocktail DLC79 Suppresses Gliomagenesis by Activating Ascl1 and Remodeling Transcriptome. (PubMed, Cells) - "Using phenotype-driven screening, we identified a multi-target small-molecule cocktail DLC79 (DAPT, LDN193189, CHIR99021, I-BET762, and Isx9) that effectively reprograms human glioma cells into neuron-like cells by activating endogenous ASCL1 (174.4-fold) and remodeling the transcriptional landscape...In a subcutaneous xenograft model, brief pretreatment with DLC79 significantly attenuated the tumorigenic potential of glioma cells, reducing tumor bioluminescence by 56% and tumor mass by 47%. Our study establishes pharmacological reprogramming as a promising anti-glioma strategy that leverages neuronal conversion to reduce oncogenic properties, thereby initiating a novel therapeutic paradigm."

Journal • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • ASCL1

Epigenetic suppression of synovial inflammation and osteoclast differentiation in rheumatoid arthritis by I-BET762. (PubMed, Sci Rep) - "These data suggest that I-BET762 inhibit synovial inflammation and bone resorption in RA. In vivo animal experiment may be needed for confirmation."

Journal • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • BRD3 • BRD4 • CXCL10 • CXCL8 • IL6 • MMP1 • MYC

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. (PubMed, JNCI Cancer Spectr) - "Once-daily molibresib was tolerated at doses demonstrating target engagement. Preliminary data indicate proof-of-concept in NC."

Journal • P1 data • Fatigue • Hematological Disorders • NUT Midline Carcinoma • Oncology • Testicular Cancer • Thrombocytopenia • CCL2

A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies. (PubMed, Clin Cancer Res) - P2 | "While anti-tumor activity was observed with molibresib, use was limited by gastrointestinal and thrombocytopenia toxicities. Investigations of molibresib as part of combination regimens may be warranted."

Journal • P1/2 data • Acute Myelogenous Leukemia • Cutaneous T-cell Lymphoma • Febrile Neutropenia • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia

Decoding Bromodomain and Extra-Terminal Domain Protein-Mediated Epigenetic Mechanisms in Human Uterine Fibroids. (PubMed, Int J Mol Sci) - "To investigate the biological effects of BET proteins, two small-molecule inhibitors, JQ1 and I-BET762, were used to assess their impact on UF cell behavior and transcriptomic profiles. Collectively, these results support that BET proteins play a pivotal role in regulating key signaling pathways and cellular processes in UFs. Targeting BET proteins may therefore represent a promising non-hormonal therapeutic strategy for UF treatment."

Journal • Gynecology • Inflammation • Oncology • Solid Tumor • Uterine Leiomyoma • Women's Health • BRD4 • TNFA

Identifying ARRB2 as a Prognostic Biomarker and Key Player in the Tumor Microenvironment of Pancreatic Cancer through scPagwas Methodology. (PubMed, Curr Gene Ther) - "Macrophages, along with ARRB2, serve an essential function in the progression of PAAD and immune regulation. The identification of ARRB2 as a prognostic biomarker and its involvement in critical oncogenic pathways furnish a theoretical foundation for targeted therapeutic interventions. These discoveries contribute to the ongoing exploration of diagnostic, prognostic, and treatment strategies for PAAD."

Biomarker • Journal • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

A drug response prediction method for single-cell tumors combining attention networks and transfer learning. (PubMed, Front Med (Lausanne)) - "It accurately predicted the sensitivity and resistance of mouse acute myeloid leukemia cells to I-BET-762 and the sensitivity and resistance of human oral squamous cell carcinoma cells to cisplatin. ATSDP-NET identifies critical genes linked to drug responses, confirming its predictions through differential gene expression scores and gene expression patterns. This method provides valuable insights into the mechanisms of drug resistance and offers potential for developing personalized treatment strategies."

Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Oral Cancer • Squamous Cell Carcinoma

A prognostic model for multiple myeloma based on lipid metabolism related genes. (PubMed, Zhong Nan Da Xue Xue Bao Yi Xue Ban) - "LRGs serve as promising biomarkers for prognosis prediction and risk stratification in MM. The overexpression of chromosomal instability-related and high-risk genetic event-associated genes in high-risk patients may explain their poorer outcomes. Given the observed resistance to bortezomib and lenalidomide in high-risk patients, combination therapies involving BMS-754807 or I-BET-762 may represent effective alternatives."

Journal • Hematological Disorders • Hematological Malignancies • Metabolic Disorders • Multiple Myeloma • Oncology • B2M • FGFR3

Positional isomers of Indolyl-benzodiazepines display dissimilar binding and recruitment of BET transcriptional regulators to targeted genomic loci. (PubMed, Bioorg Chem) - "BET proteins contain two tandem bromodomains (BD1 and BD2) that bind histone acetyl-lysine residues that can be targeted with small molecule inhibitors such as IBET-762, which bears a triazolo benzodiazepine core...The relative activity of each SynGR corresponded to the affinity of the tethered BET ligand for the BD2 domain. The development and structure-activity relationship analysis of these BET ligands provides a blueprint for the construction of increasingly selective BET inhibitors and proximity-inducing molecules."

Journal

Machine learning-based diagnostic and prognostic models for breast cancer: a new frontier on the clinical application of natural killer cell-related gene signatures in precision medicine. (PubMed, Front Immunol) - "Furthermore, drug sensitivity analysis indicated that high-risk patients were more sensitive to Thapsigargin, Docetaxel, AKT inhibitor VIII, Pyrimethamine, and Epothilone B, while showing higher resistance to drugs such as I-BET-762, PHA-665752, and Belinostat. This study provides a comprehensive analysis of NRGs in BC and establishes reliable ML-based diagnostic and prognostic models. The findings highlight the clinical relevance of NRGs in BC progression, immune regulation, and therapy response, offering potential targets for personalized treatment strategies."

Biomarker • Gene Signature • IO biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • CD2 • IL21 • PRDX1 • ULBP2

An MHC-Related Gene's Signature Predicts Prognosis and Immune Microenvironment Infiltration in Glioblastoma. (PubMed, Int J Mol Sci) - "We further propose I-BET-762 and Enzastaurin as potential therapeutic candidates for glioma. In conclusion, the four-gene signature we identified and the corresponding risk score model constructed from it provide valuable tools for the prognosis prediction of glioblastoma multiforme (GBM) and may guide personalized treatment strategies. The least absolute shrinkage and selection operator (LASSO) risk score has demonstrated significant prognostic evaluation utility in clinical GBM patients, bringing potential implications for patient stratification and the optimization of treatment regimens."

Biomarker • Journal • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • FCGR2B • MXRA5 • TNFRSF9 • TNFSF14

SIlencing BRD4 to increase NK cell activity for adoptive cell therapy: a novel self-delivering RNAi approach (ITOC 2025) - "Current BET inhibitors such as JQ1 and molibresib target BRD4 but lack specificity, leading to off-target effects that limit their clinical application...Conclusions Incorporating PH-894 treatment into ex vivo NK cell expansion protocols prior to ACT represents a promising strategy for improving NK cell efficacy. These findings suggest that BRD4 may play an important role in regulating NK cell activity and that its silencing may modulate NK cell function, potentially enhancing their antitumor activity. This study provides a foundation for further exploration of BRD4 as a target for enhancing NK cell-based immunotherapies."

IO biomarker • Oncology • BRD4 • IL2RA • KLRD1 • NCAM1

A high-throughput, microplate reader-based method to monitor in vitro HIV latency reversal in the absence of flow cytometry. (PubMed, Virology) - "We show that HIV reactivation by control LRAs like prostratin and romidepsin is readily detected with dose dependence and with significant correlation and sensitivity to standard flow cytometry. Using this method, we screen 79 epigenetic modifiers and identify CUDC-101, molibresib, and quisinostat as novel LRAs. This microplate reader-based method offers accessibility to researchers in resource-limited regions to work with J-Lat cells and more actively participate in global HIV cure research efforts."

Journal • Preclinical • Human Immunodeficiency Virus • Infectious Disease • CD4

The BRD4 Inhibitor I-BET-762 Reduces HO-1 Expression in Macrophages and the Pancreas of Mice. (PubMed, Int J Mol Sci) - "When the bromodomain inhibitor I-BET-762 was used to treat macrophages or mice with pancreatitis, high levels of HO-1 were reduced. This study shows that bromodomain inhibitors can be used to prevent physiological responses to inflammation that promote tumorigenesis."

Journal • Preclinical • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Pancreatitis • Solid Tumor • BRD4 • HMOX1 • KRAS • NFE2L2 • PDX1

A high-throughput, microplate reader-based method to monitor in vitro HIV latency reversal in the absence of flow cytometry. (PubMed, bioRxiv) - "We show that HIV reactivation by control LRAs like prostratin and romidepsin is readily detected with dose dependence and with significant correlation and sensitivity to standard flow cytometry...Using this method, we screen 79 epigenetic modifiers and identify molibresib, quisinostat, and CUDC-101 as novel LRAs. This microplate reader-based method offers accessibility to researchers in resource-limited regions to work with J-Lat cells and more actively participate in global HIV cure research efforts. J-Lat T-cell lines are important to HIV cure research but require flow cytometryWe describe a method to work with J-Lat cells using a standard microplate readerThis assay can detect control LRAs similar to flow cytometry and discover new LRAsThis assay allows low-resourced laboratories to contribute to HIV cure research."

Journal • Preclinical • Human Immunodeficiency Virus • Infectious Disease • CD4

Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine Leiomyosarcoma. (PubMed, Cells) - "Furthermore, inhibiting BET proteins with their small, potent inhibitors (JQ1 and I-BET 762) significantly inhibited the uLMS proliferation dose-dependently via cell cycle arrest. The connections between BET proteins and crucial biological pathways provide a fundamental structure to better understand uterine diseases, particularly uLMS pathogenesis. Accordingly, targeting the vulnerable epigenome may provide an additional regulatory mechanism for uterine cancer treatment."

Journal • Leiomyosarcoma • Oncology • Sarcoma • Solid Tumor • Uterine Cancer • Uterine Corpus Leiomyosarcoma • BRD2 • BRD3 • BRD4

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=124 | Terminated | Sponsor: GlaxoSmithKline | Phase classification: P1/2 ➔ P1

Phase classification • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

Effect of BET inhibitors on oral squamous cell carcinoma cell line and its' CD44 positive subpopulation (EACR 2024) - "Despite advancements in OSCC management, survival rates remain suboptimal, and the development of novel anti-neoplastic agents is needed.Material and Methods The study investigated the effects of three BET inhibitors (JQ1, iBET-151, iBET-762) on oral squamous cell carcinoma cell line (SCC-25) and its' CD44 positive subpopulation. Conclusion Results of the study indicate better antitumor effect of BET inhibitors on CD44+ population of tumor cells during prolonged treatment of tumor cells. New investigations should provide more insight into mechanism of action of BET inhibitors on specific oral cancer cells subpopulations."

Preclinical • Oncology • Oral Cancer • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD44

Pharmacological targeting of histone H3K27 acetylation/BRD4-dependent induction of ALDH1A3 for early-phase drug tolerance of gastric cancer. (PubMed, Cancer Res Commun) - "ChIP-PCR and ChIP-seq analyses revealed that histone H3 lysine 27 acetylation was enriched in the ALDH1A3 promoter in 5-Fluorouracil (5-FU)-tolerant persister PDCs. By chemical library screening, we found that the BET inhibitors OTX015/birabresib and I-BET-762/molibresib suppressed DTP-related ALDH1A3 expression and preferentially inhibited DTP cell growth...Combination therapy with 5-FU and OTX015 significantly suppressed in vivo tumor growth. These observations suggest that BET inhibitors are efficient DTP cell-targeting agents for gastric cancer treatment."

Journal • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • ALDH1A3 • BRD2 • BRD4

Role of bromodomain extra terminal inhibitor (BETi) in combination with radiotherapy for the treatment of NF1-associated malignant peripheral nerve sheath tumor (AACR 2024) - "Mice were segregated into vehicle and I-BET 762 treatment groups and treated with either vehicle or drug for one week before the RT was initiated... Genetic mutations in NF-1-associated MPNST tumors result in susceptibility to BETi treatment. In a PDX model of PRC2 wild-type tumors, BETi treatment resulted in tumor regression and sensitized MPNST xenografts to RT. Combining BETi and RT enhanced tumor death and increased expression of genes associated with DNA damage and apoptosis."

Combination therapy • Brain Cancer • Neurofibrosarcoma • Oncology • Sarcoma • Solid Tumor • CASP3 • ERCC4 • NF1 • RAD50 • RAD51D • XRCC1

Enhancing selectivity and overcoming tissue-specific toxicity in drug discovery: A novel BET inhibitor with targeted delivery for prostate cancer treatment (AACR 2024) - "We engineered a novel BET-selective chemotype conjugated to a Prostate-Cancer specific targeting component in order to overcome the off-tissue effects of state-of-the-art BET inhibitors.To achieve delivery of the compound, we modified the benzodiazepine (BzD) scaffold of the well-established BET inhibitor I-BET762, conjugating the tertiary amine with a self-immolating motif, allowing for intracellular compound release upon an enzymatic trigger...Moreover, we established the transcriptional rationale for loss of cellular fitness using RNA sequencing, discovering strong down-regulation of solute carriers, depriving cells of nutrient flux and disrupting normal processes.Furthermore, RT53 exhibits antitumor activity in vivo, in localized models of prostate cancer established in male athymic nude mice. The targeted delivery of RT53 demonstrated superior efficacy in vivo ameliorating on-target, off-tissue toxicity, as low-dose treatment led to almost complete elimination of..."

Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • MYC

BRD4 inhibitors broadly promote erastin-induced ferroptosis in different cell lines by targeting ROS and FSP1. (PubMed, Discov Oncol) - "BRD4 inhibition by JQ-1 and I-BET-762 or BRD4 knockdown resulted in substantial accumulation of reactive oxygen species (ROS) in both HEK293T and HeLa cells. Our results suggest that ROS accumulation and FSP1 downregulation are common mechanisms underlying increased ferroptosis with BRD4 inhibitors. Thus, BRD4 inhibitors might be more effective in combination with ferroptosis inducers, especially in FSP1-dependent cancer cells."

Journal • Preclinical • Oncology • AIFM2 • BRD4 • FTH1 • GPX4 • VDAC3

Inhibition of Bromodomain Proteins Enhances Oncolytic HAdVC5 Replication and Efficacy in Pancreatic Ductal Adenocarcinoma (PDAC) Models. (PubMed, Int J Mol Sci) - "RNAseq analysis demonstrated that the inhibitors increased viral E1A expression, altered expression of cell cycle regulators and inflammatory factors, and attenuated expression levels of tumour cell oncogenes such as c-Myc and Myb. The data suggest that the tumour-selective Ad∆∆ and Ad-3∆-A20T combined with epigenetic inhibitors is a novel strategy for the treatment of PDAC by eliminating both cancer and associated stromal cells to pave the way for immune cell access even after systemic delivery of the virus."

Journal • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • BRD4 • MYC

Cytoplasmic Accumulation of Histones Induced by BET Inhibition Protects Cells from C9orf72 Poly(PR)-Induced Cell Death. (PubMed, Adv Biol (Weinh)) - "Further investigation reveals that BRD4 inhibitors, such as JQ-1 and I-BET762, restrict cytoplasmic localization of PR20, thereby reducing its cytotoxic effect. In addition, phenylephrine (PE) induces cellular hypertrophy and cytoplasmic distribution of histone, which also helps protect cells from PR20-induced cell death. The research suggests that temporarily inducing the presence of cytoplasmic histones may alleviate the neurotoxic effects of dipeptide repeat proteins."

Journal • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Dementia • Frontotemporal Lobar Degeneration • BRD4

A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer (Clin Cancer Res) - P1/2 | N=124 | NCT02964507 | Sponsor: GlaxoSmithKline | "The study included 123 patients. The most common treatment-related adverse events (AE) were nausea (52%), dysgeusia (49%), and fatigue (45%). At a 60-mg dosage of molibresib, >90% of patients experienced treatment-related AE. Grade 3 or 4 treatment-related AE were observed in 47% and 48% of patients treated with molibresib 60 mg and molibresib 80 mg, respectively. The ORR was 13% [95% confidence interval (CI), 8–20], not meeting the 25% threshold for proceeding to phase II. Among 82 patients with detected circulating tumor DNA and clinical outcome at study enrollment, a strong association was observed between the detection of copy-number amplification and poor progression-free survival (HR, 2.89; 95% CI, 1.73–4.83; P < 0.0001)."

P1/2 data • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer